Ketorolac tromethamine nasal spray

Abstract

The invention provides a ketorolac tromethamine nasal spray. A spraying device comprises a spraying bottle and a spraying head, and is characterized in that the spraying bottle comprises a casing (1) and a liner (2) with the volume of 1.5 ml; the liner of the spraying bottle is in a shape of a cylinder, the combination of a cylinder and a cone, or the combination of a cylinder, a cone and a cylinder with a smaller diameter ; the casing of the spraying bottle has the same appearance, size and connector part as those of a conventional 10 ml spray sold in the market; and the spraying head adopts a praying head of the conventional 10 ml spray sold in the market. The ketorolac tromethamine nasal spray has the advantages of few residues, high safety and multiple effective spraying times, the production cost can be reduced, and the medicine waste is prevented.

Description

Technical field: [0001] The invention relates to a ketorolac tromethamine nasal spray, in particular to a ketorolac tromethamine nasal spray which adopts a spray bottle with a volume of 1.5ml. Background technique: [0002] Ketorolac tromethamine is a non-steroidal anti-inflammatory drug that produces analgesic effects by inhibiting the biosynthesis of prostaglandins. It is used for short-term treatment of acute and severe pain, usually for postoperative analgesia, not applicable For the treatment of mild or chronic pain. The drug acts on the peripheral nervous system, so it generally has no adverse effects on the central nervous system. The drug has the advantages of no addiction, no dependence, no respiratory depression, no irritation to tissues, and no peculiar smell. [0003] Ketorolac tromethamine was first marketed abroad (1989) in the form of injection, the original manufacturer was Roche, the specifications: 15, 30mg / ml, and the trade name: TORADOL. Roche launched...

AI Technical Summary

Problems solved by technology

Oral, intramuscular and intravenous injection all have significant analgesic effects, but have the following disadvantages: 1. Intramuscular injection often causes discomfort; 2. Intravenous injection is inconvenient; Weak, especially not suitable for elderly patients and critically ill patients with dysphagia

4. There are many adverse reactions, and there have been reports of death due to gastrointestinal bleeding, postoperative bleeding, acute renal insufficiency and allergic reactions

[0005] The ketorolac tromethamine nasal spray produced by LUITPOLD is filled with the liquid medicine in an ordinary spray bottle. Due to the large volume of the spray bottle, the small volume of the medicine liquid only exists at the bottom of the spray bottle, and the liquid surface The height is low, and the depth of the immersion pipette is insufficient, resulting in incomplete absorption of the liquid medicine, resulting in fewer effective spray times, more residues, and large waste. Although the problem of insufficient effective spray times can be solved by increasing the filling volume of the liquid medicine Defects, but further increase the waste of expensive liquid medicine, resulting in high drug prices and increasing the financial burden on patients

Images